Loading...
•
Sep 26, 2025
Danaher Q3 2025 Earnings Report
Danaher reported solid third-quarter results, exceeding expectations on revenue, earnings, and cash flow.
Key Takeaways
Danaher delivered a strong Q3 with higher-than-expected revenue and earnings, driven by bioprocessing momentum and Cepheid's respiratory business.
Forward Guidance
Danaher expects low-single-digit core revenue growth and adjusted EPS of $7.70 to $7.80 for full year 2025.
Positive Outlook
- Maintains strong adjusted EPS guidance of $7.70–$7.80
- Bioprocessing momentum expected to continue
- Respiratory revenue at Cepheid exceeding expectations
- Continued investment in breakthrough innovation
- Productivity gains expected to strengthen competitive position
Challenges Ahead
- Life Sciences segment facing a slight decline
- Diagnostics growth expected to be flat in Q4
- Currency exchange remains a headwind
- Uncertainty in global healthcare markets
- Cost pressures from restructuring and intangible impairments
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...